Combination with vorinostat overcomes ABT-263 (navitoclax) resistance of small cell lung cancer

Small cell lung cancer (SCLC) is an aggressive tumor type with high mortality. One promising approach for SCLC treatment would be to utilize agents targeting molecular abnormalities regulating resistance to apoptosis. BH3 mimetic antagonists, such as ABT-737 and its orally available derivative ABT-2...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Cancer Biol Ther
Autores principales: Nakajima, Wataru, Sharma, Kanika, Hicks, Mark A., Le, Ngoc, Brown, Rikiara, Krystal, Geoffrey W., Harada, Hisashi
Formato: Artigo
Lenguaje:Inglês
Publicado: Taylor & Francis 2015
Materias:
Research Paper
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4847809/
https://ncbi.nlm.nih.gov/pubmed/26575826
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384047.2015.1108485
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares